Lung Cancer
Conditions
Keywords
Lung cancer screening
Brief summary
This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.
Detailed description
This is a prospective, longitudinal, single-center interventional study of AI lung cancer prediction tests with return of results at the University of Illinois Hospital clinics. The purpose is to evaluate patient-reported outcomes of AI risk inference. The motivation for the study was based on findings that existing AI tests have been designed without including patient populations like those at UI Health. Using newer, more generalizable AI tests, UI Health researchers will evaluate patient perceptions of AI risk and how that impacts their beliefs about their health and lung cancer screening. The study will enroll up to 200 screen-naïve and up to 200 screen-established participants, at least 100 and no more than 400 participants, as defined by the eligibility criteria, over an anticipated enrollment period of approximately 12 months. Recruitment strategies to identify potential participants may include identification of participants through electronic health records, emails, recruitment campaigns, and other outreach strategies. Two cohorts will be studied: A) Individuals eligible for lung cancer screening by the USPSTF who have never undergone lung cancer screening with low-dose CT will receive a regulatory cleared laboratory developed test for lung cancer screening eligible patients. B) For USPSTF-eligible individuals who have already received low-dose CT screening, these individuals will receive a research-use-only (RUO) multimodal AI risk prediction that has been validated on UI Health patients. Multimodal AI risk prediction was developed by UIC researchers to predict long-term lung cancer risk by AI inference of lung screening CT images and clinical characteristics from a diverse patient population.
Interventions
DIAGNOSTIC_TESTArtificial Intelligence (AI) test
Individuals eligible for lung cancer screening by the USPSTF who have never undergone lung cancer screening with low-dose CT will receive a regulatory cleared laboratory developed blood test for lung cancer screening, circulating DNA fragmentomics
DIAGNOSTIC_TESTResearch-use-only multimodal AI risk model
For USPSTF-eligible individuals who have already received low-dose CT screening, these individuals will receive a research-use-only (RUO) multimodal artificial intelligence risk prediction based on lung screening CT imaging and clinical features.
Sponsors
University of Illinois at Chicago
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must be 50-80 years of age, inclusive, at the time of signing the Informed Consent Form (ICF). * Participants must be eligible for LDCT screening as defined by the USPSTF * USPSTF-eligible patients at UI Health and Mile Square FQHC, including primary care and substance use disorder clinics. * Adults who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. * Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. Consent provided by a legally authorized representative is not permitted in this protocol. * Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. * Ability of the subject to understand and comply with study procedures for the entire length of the study.
Exclusion criteria
* Adults who have more than 20 pack-years history but who have not smoked for 15 years or more prior to informed consent (i.e., quit smoking for 15 or more years). * Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality). * Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 5 years prior to the expected enrollment date, or diagnosed greater than 5 years prior to the expected enrollment date and never treated. Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded. * Prior/Concurrent Concomitant Therapy (Medications/Treatments): Definitive treatment for invasive solid tumor or hematologic malignancy within the 5 years prior to the expected enrollment date. Adjuvant hormone therapy for cancer (e.g., for breast or prostate cancer) is not an exclusion criterion. * Individuals who will not be able to comply with the protocol procedures. * Individuals who are not currently registered patients at UIH * Current pregnancy (by self-report of pregnancy status)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Reported Outcomes Measurement Information System (PROMIS) survey results before and following the return of results (ROR) | Day 1 through 30 days post-return of results survey, or approximately Day 60 | To evaluate participant reported outcomes before and after return of results (ROR) using the PROMIS test surveys |
| Multidimensional Impact of Cancer Risk Assessment (MICRA) following return of results (ROR) | Day 1 through 30 days post-return of results survey, or approximately Day 60 | To evaluate participants' MICRA score following the return of results (ROR) |
| Perceptions and health beliefs relating to lung cancer screening using the Lung Health Belief Scale (Lung-HBS) perceived risk and perceived benefits after the return of results (ROR) | Day 1 through 30 days post-return of results survey, or approximately Day 60 | To evaluate the perceptions and health beliefs of participants related to lung cancer screening |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rates of participant adherence to LDCT and smoking cessation within one year of return of results (ROR). | Screening through 1 year post-return of results | To evaluate rates of participant adherence to LDCT and smoking cessation which will be measured as the proportion of patients who utilize low dose CT (LDCT) screening in both screening naïve and screening established cohorts within 1 year of ROR, and the proportion who cease smoking 1 year after ROR. |
Countries
United States
Contacts
CONTACTAmeen Salahudeen, MD, PhD
CONTACTErica Seltzer, DrPh, MPH
PRINCIPAL_INVESTIGATORAmeen Salahudeen, MD, PhD
University of Illinois at Chicago
Outcome results
None listed